UnfoldIP

Company patents

Metagenomi, Inc.

Metagenomi, Inc. is strategically expanding its patent portfolio, with a notable shift towards Pharmaceutical Preparations, which now constitutes 13.0% of its total patents and has seen a remarkable 100.0% year-over-year growth so far in 2026, indicating an emerging focus in this area. This expansion is accompanied by a significant decline in Peptides & Proteins, which saw a -100.0% YoY change, suggesting a reprioritization of its R&D efforts.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

46 US filings (since 2023) · 2 categories · 1 themes

Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Pharmaceutical PreparationsPeptides & Proteins
Who else files here? →
13since 2023
0.0%YoY

Patents

Showing 1-10 of 48

Page 1 of 5
US 20260146263 A1APPLICATION
C12N15/90

GENE EDITING SYSTEMS COMPRISING REVERSE TRANSCRIPTASES

Filed:2023-10-18Pub:2026-05-28
Applicant:Metagenomi, Inc.

The disclosure relates generally to gene editing systems comprising reverse transcriptases and fusion proteins of reverse transcriptases with nickases or nucleases, methods of making such reverse transcriptases and fusion proteins, and methods of using such reverse transcriptases and fusion proteins for site directed genome editing in cells.

US 20260132392 A1APPLICATION
C12N9/22

GENE EDITING SYSTEMS COMPRISING REVERSE TRANSCRIPTASES

Filed:2023-10-18Pub:2026-05-14
Applicant:Metagenomi, Inc.

The disclosure relates generally to gene editing systems comprising reverse transcriptases and fusion proteins of reverse transcriptases with nickases or nucleases, methods of making such reverse transcriptases and fusion proteins, and methods of using such reverse transcriptases and fusion proteins for site directed genome editing in cells.

US 20260115321 A1APPLICATION
A61K48/00

SUPPLEMENTATION OF LIVER ENZYME EXPRESSION

Filed:2025-12-23Pub:2026-04-30
Applicant:Metagenomi, Inc.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

US 20260115320 A1APPLICATION
A61K48/00

SUPPLEMENTATION OF LIVER ENZYME EXPRESSION

Filed:2025-12-23Pub:2026-04-30
Applicant:Metagenomi, Inc.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

US 20260115319 A1APPLICATION
A61K48/00

SUPPLEMENTATION OF LIVER ENZYME EXPRESSION

Filed:2025-12-23Pub:2026-04-30
Applicant:Metagenomi, Inc.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

US 20260078412 A1APPLICATION
C12N15/90

ENDONUCLEASE SYSTEMS

Filed:2025-07-29Pub:2026-03-19
Applicant:Metagenomi, Inc.

The present disclosure provides for endonuclease enzymes as well as methods of using such enzymes or variants thereof.

US 12533424 B2GRANTED
A61K48/00

Supplementation of liver enzyme expression

Filed:2024-11-25Pub:2026-01-27
Applicant:Metagenomi, Inc.

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.

US 12503710 B2GRANTED
C12N15/90

Base editing enzymes

Filed:2024-05-02Pub:2025-12-23
Applicant:Metagenomi, Inc.

The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

US 12435323 B2GRANTED
C12N9/22

Enzymes with RUVC domains

Filed:2024-02-26Pub:2025-10-07
Applicant:Metagenomi, Inc.

The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

US 12410449 B2GRANTED
C12N9/22

Endonuclease systems

Filed:2024-05-21Pub:2025-09-09
Applicant:Metagenomi, Inc.

The present disclosure provides for endonuclease enzymes as well as methods of using such enzymes or variants thereof.

12345